Stocks Industrials TXG
NASDAQ · Industrials10x Genomics, Inc. (TXG)
10x Genomics, Inc. brought in $618.6M of revenue over the twelve months to September 30, 2026, down 3.6% from a year earlier. It posted a net loss of $67.1M. Operating cash flow minus capital spending left $130.1M of free cash flow in fiscal 2025. At September 30, 2026 it held $526.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about 10x Genomics, Inc.
- Net worth
- 10x Genomics, Inc. has a market value (market cap) of $8.2B at the latest share price, and shareholders' equity of $838M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $642.8M (+5.2% year on year), with a net loss of $43.5M. Over the 12 months to September 30, 2026: revenue $618.6M, net loss $67.1M.
- Cash flow
- In fiscal 2025 operations brought in $136.1M of cash; after $5.9M of capital spending, free cash flow was $130.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- 10x Genomics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What 10x Genomics, Inc. does
10x Genomics, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker TXG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $642.8M | -$43.5M | -$0.35 | $130.1M |
| 2024 | $610.8M | -$182.6M | -$1.52 | -$5.7M |
| 2023 | $618.7M | -$255.1M | -$2.18 | -$63.8M |
| 2022 | $516.4M | -$166M | -$1.46 | -$165.3M |
| 2021 | $490.5M | -$58.2M | -$0.53 | -$122.7M |
| 2020 | $298.8M | -$542.7M | -$5.37 | -$254.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TXG ranks in Industrials
Latest SEC filings
What 10x Genomics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 1.1% to $150.7M versus the same quarter last year; diluted EPS -$0.15 versus -$0.22.
- November 5, 2026
- November 2, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 13% to $151M versus the same quarter last year; diluted EPS -$0.14 versus $0.28.
- August 6, 2026
- June 8, 2026
- May 8, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 2.6% to $150.8M versus the same quarter last year; diluted EPS -$0.10 versus -$0.28.
What is TXG worth? A DCF from its reported cash flow
Insider trades
What the people running 10x Genomics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $11.1M worth of shares in the last 90 days and bought none on the open market. Most of the selling (61%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 22, 2026 | Saxonov SergeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,000 | $78.2K |
| September 22, 2026 | Saxonov SergeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,000 | $159.2K |
| September 22, 2026 | Saxonov SergeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 9,300 | $752.4K |
| September 22, 2026 | Saxonov SergeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 9,900 | $810.1K |
| September 22, 2026 | Saxonov SergeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,800 | $230.6K |
| September 22, 2026 | Suliman ShehnaazDirector | Soldpre-planned (10b5-1) | 292 | $22.8K |
| September 22, 2026 | Suliman ShehnaazDirector | Soldpre-planned (10b5-1) | 614 | $48.8K |
| September 22, 2026 | Suliman ShehnaazDirector | Soldpre-planned (10b5-1) | 1,325 | $107.1K |
Who owns TXG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15.6% | March 6, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 11.7% | September 8, 2026 |
| Vanguard Portfolio Management13G, passive | 5.93% | April 28, 2026 |
| Vanguard Capital Management13G, passive | 5.24% | April 29, 2026 |
| ARK Investment Management LLC13G, passive with 1 related filers | 5.22% | October 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 391 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 17,629,266 | -111,706 |
| BlackRock, Inc. | 10,804,070 | +724,157 |
| ARK Investment Management LLC | 10,003,057 | -1,714,260 |
| Vanguard Portfolio Management LLC | 6,982,492 | +69,556 |
| Quantinno Capital Management LP | 5,469,698 | +57,937 |
| Vanguard Capital Management LLC | 5,082,594 | -186,992 |
| Sumitomo Mitsui Trust Group, Inc. | 4,194,627 | -915,587 |
| Amova Asset Management Americas, Inc. | 4,192,517 | -911,661 |
| Morgan Stanley | 3,351,911 | +695,558 |
| Goldman Sachs Group Inc | 3,148,859 | -822,941 |
| Geode Capital Management, LLC | 3,082,790 | +178,562 |
| State Street Corp | 2,801,437 | +212,642 |
| Citadel Advisors LLC | 2,779,213 | +2,035,479 |
| Dimensional Fund Advisors LP | 2,225,284 | +182,334 |
| Jacobs Levy Equity Management, Inc | 2,019,883 | -263,541 |
| Aqr Capital Management LLC | 2,026,464 | -511,792 |
| Point72 Asset Management, L.P. | 1,852,776 | new |
| Capital World Investors | 1,493,031 | +40,731 |
| Northern Trust Corp | 1,144,027 | +96,022 |
| Nuveen, LLC | 1,124,633 | +498,837 |
Insiders
9 insiders reported holding 2,423,661 shares in total, about $152.4M at the last price.
| Holder | Shares |
|---|---|
| Saxonov SergeChief Executive Officer, Director | 1,050,249 |
| Hindson Benjamin J.See Remarks, Director | 488,182 |
| Stuelpnagel John RDirector | 328,436 |
| Taich AdamChief Financial Officer | 316,344 |
| Mateo AlanDirector | 85,877 |
| Kosaraju SridharDirector | 65,278 |
| Popovits Kimberly JDirector | 37,445 |
| Teichmann Sarah A.Director | 28,058 |
| Suliman ShehnaazDirector | 23,792 |
Questions about TXG
What does 10x Genomics, Inc. do?
10x Genomics, Inc. is a company in the Industrials sector, listed on NASDAQ as TXG. Its shares trade on NASDAQ under the ticker TXG.
What is 10x Genomics, Inc.'s net worth?
10x Genomics, Inc. has a market value (market cap) of $8.2B at the latest share price, and shareholders' equity of $838M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is 10x Genomics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $67.1M on revenue of $618.6M.
How much revenue does 10x Genomics, Inc. make?
Over the twelve months to September 30, 2026 10x Genomics, Inc. reported revenue of $618.6M. That is 3.6% less than a year earlier.
When did 10x Genomics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is 10x Genomics, Inc.'s next earnings report?
10x Genomics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TXG with
Follow TXG
Get an email when 10x Genomics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values 10x Genomics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.